Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register...
Covered in this story
What has happened since
- Incyte is down 6.4% since this was published, 29 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Incyte
- H.C. Wainwright: $125 → $152 by Sep 2027 · Buy via Investing.com
- Oppenheimer: $130 → $120 by Jul 2027 · Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $INCY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Incyte →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.